Market closed

Profound Medical/$PROF

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Profound Medical

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

Ticker

$PROF
Sector
Health Care
Trading on
NASDAQ

Industry

Health Care Equipment & Supplies

Headquarters

Mississauga, Canada

Employees

131
Website
www.profoundmedical.com

Profound Medical Metrics

BasicAdvanced
$218M
-
-$1.33
0.83
-

$218M

0.83

$11.42

$6.78

102K

6.123

5.115

12.114

20.049

-48.87%

-44.62%

-90.17%

19.228

8.27

8.36

-6.957

39.35%

-4.28%

0.86%

-1.53%

What the Analysts think about Profound Medical

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Profound Medical stock.

Profound Medical Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Profound Medical Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Profound Medical News

AllArticlesVideos
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

GlobeNewsWire·7 days ago
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·1 week ago
Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PROF

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Profound Medical stock?

Profound Medical (PROF) has a market cap of $218M as of January 15, 2025.

What is the P/E ratio for Profound Medical stock?

The price to earnings (P/E) ratio for Profound Medical (PROF) stock is 0 as of January 15, 2025.

Does Profound Medical stock pay dividends?

No, Profound Medical (PROF) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Profound Medical dividend payment date?

Profound Medical (PROF) stock does not pay dividends to its shareholders.

What is the beta indicator for Profound Medical?

Profound Medical (PROF) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.